The University of Chicago Header Logo

Connection

David A. Ehrmann to Adult

This is a "connection" page, showing publications David A. Ehrmann has written about Adult.
Connection Strength

0.631
  1. Longitudinal relationship of diabetes-related distress and depressive symptoms: analysing incidence and persistence. Diabet Med. 2015 Oct; 32(10):1264-71.
    View in: PubMed
    Score: 0.035
  2. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.028
  3. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov; 26(11):3138-46.
    View in: PubMed
    Score: 0.027
  4. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb; 96(2):365-74.
    View in: PubMed
    Score: 0.025
  5. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.023
  6. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct; 93(10):3878-84.
    View in: PubMed
    Score: 0.021
  7. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):48-53.
    View in: PubMed
    Score: 0.018
  8. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):36-42.
    View in: PubMed
    Score: 0.018
  9. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jan; 90(1):66-71.
    View in: PubMed
    Score: 0.016
  10. Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jun; 89(6):2973-6.
    View in: PubMed
    Score: 0.016
  11. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun; 66(3):356-62.
    View in: PubMed
    Score: 0.016
  12. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.015
  13. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Sep; 87(9):4297-300.
    View in: PubMed
    Score: 0.014
  14. Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
    View in: PubMed
    Score: 0.014
  15. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Apr; 87(4):1669-73.
    View in: PubMed
    Score: 0.014
  16. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
    View in: PubMed
    Score: 0.014
  17. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002 Feb; 87(2):772-5.
    View in: PubMed
    Score: 0.014
  18. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021 12; 44(12):2775-2782.
    View in: PubMed
    Score: 0.013
  19. Effect of Medical and Surgical Interventions on a-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care. 2021 09; 44(9):1948-1960.
    View in: PubMed
    Score: 0.013
  20. Hyperglucagonemia Does Not Explain the ß-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care. 2021 09; 44(9):1961-1969.
    View in: PubMed
    Score: 0.013
  21. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001 May; 86(5):2027-31.
    View in: PubMed
    Score: 0.013
  22. Obstructive Sleep Apnea, Glucose Tolerance, and ß-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 04; 44(4):993-1001.
    View in: PubMed
    Score: 0.013
  23. Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
    View in: PubMed
    Score: 0.011
  24. Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes. Diabetes Care. 2019 07; 42(7):1326-1332.
    View in: PubMed
    Score: 0.011
  25. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan; 22(1):141-6.
    View in: PubMed
    Score: 0.011
  26. Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2018 02 01; 103(2):486-496.
    View in: PubMed
    Score: 0.010
  27. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.010
  28. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.010
  29. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.009
  30. How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). Diabet Med. 2016 06; 33(6):835-43.
    View in: PubMed
    Score: 0.009
  31. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015 Aug 18; 6:7502.
    View in: PubMed
    Score: 0.009
  32. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.009
  33. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.008
  34. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994 Dec; 79(6):1686-92.
    View in: PubMed
    Score: 0.008
  35. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12):4565-92.
    View in: PubMed
    Score: 0.008
  36. Interactions between pregnancy, obstructive sleep apnea, and gestational diabetes mellitus. J Clin Endocrinol Metab. 2013 Oct; 98(10):4195-202.
    View in: PubMed
    Score: 0.008
  37. Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. 2012 Oct 16; 157(8):549-57.
    View in: PubMed
    Score: 0.007
  38. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.007
  39. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.007
  40. Sleep disturbances and their relationship to glucose tolerance in pregnancy. Diabetes Care. 2011 Nov; 34(11):2454-7.
    View in: PubMed
    Score: 0.007
  41. Clinical review 10: An endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab. 1990 Jul; 71(1):1-4.
    View in: PubMed
    Score: 0.006
  42. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
    View in: PubMed
    Score: 0.006
  43. Use of nafarelin for testing pituitary-ovarian function. J Reprod Med. 1989 Dec; 34(12 Suppl):1044-50.
    View in: PubMed
    Score: 0.006
  44. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies. J Clin Endocrinol Metab. 1989 Nov; 69(5):963-7.
    View in: PubMed
    Score: 0.006
  45. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.006
  46. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 May; 94(5):1587-94.
    View in: PubMed
    Score: 0.006
  47. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.006
  48. Limitations to the use of a sensitive assay for serum thyrotropin in the assessment of thyroid status. Arch Intern Med. 1989 Feb; 149(2):369-72.
    View in: PubMed
    Score: 0.006
  49. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A. 2008 Jan 22; 105(3):1044-9.
    View in: PubMed
    Score: 0.005
  50. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
    View in: PubMed
    Score: 0.004
  51. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.004
  52. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1626-32.
    View in: PubMed
    Score: 0.003
  53. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
    View in: PubMed
    Score: 0.003
  54. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril. 1999 Aug; 72(2):360-3.
    View in: PubMed
    Score: 0.003
  55. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
    View in: PubMed
    Score: 0.002
  56. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. J Clin Endocrinol Metab. 1996 Sep; 81(9):3408-11.
    View in: PubMed
    Score: 0.002
  57. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov; 79(5):1328-33.
    View in: PubMed
    Score: 0.002
  58. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.002
  59. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1993 Feb; 76(2):450-5.
    View in: PubMed
    Score: 0.002
  60. Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males. J Clin Endocrinol Metab. 1993 Feb; 76(2):362-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.